Adverum Biotechnologies

Adverum Biotechnologies, formerly known as Avalanche Biotechnologies,[2] is a publicly traded (NASDAQ:ADVM)[3] clinical stage gene therapy company located in Redwood City, California.[4] The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).[5]

Adverum Biotechnologies
Nasdaq: ADVM
Russell 2000 Component
IndustryBiotechnology, Gene Therapy
Founded2006
Founders
HeadquartersRedwood City, California
Key people
Number of employees
100
Websiteadverum.com

History

Avalanche Biotechnologies was founded in 2006 by Tom Chalberg, Mark Blumenkranz, Mitchell Finer, and Steven Schwartz. Avalanche went public through an IPO in 2014, raising $102 million.[6]

In 2015, co-founder Tom Chalberg stepped down as CEO following Phase IIa trial results that were labeled as "iffy".[7]

In May 2016, Avalanche acquired Annapurna Therapeutics and changed its name to Adverum Biotechnologies.[8] It also changed its ticker symbol on the Nasdaq exchange from AAVL to ADVM.[8] In October 2016, former Annapurna Therapeutics CEO Amber Salzman became CEO of Adverum.[9]

In May 2018, CEO Amber Salzman left Adverum, and Chief Medical Officer Athena Countouriotis resigned after less than one year in the job.[10] In October 2018, Leone Patterson was named the new CEO of Adverum.[11]

In September 2019, Adverum announced six-month data from the first cohort of its phase I trial.[12] The stock price dropped 50% due to investor concerns over deterioration of vision that these trial subjects suffered, as well as several reports of occular inflammation.[12]

In June 2020, Laurent Fischer replaced Patterson as CEO of Adverum.[13]

In January 2022, the FDA granted Orphan Drug Designation to Adverum's ADVM-062, developed as a single intravitreal administration for blue-cone monochromacy by delivering a functional copy of the OPN1LW gene.[14]

In September 2022, Adverum announced that its first patient was dosed in the LUNA phase 2 clinical trial; the trial evaluates development for the treatment of wet age-related macular degeneration.[15][16]

References
  1. "Our Leadership Team". Adverum Biotechnologies. Retrieved 7 April 2021.
  2. "Adverum delays start of gene therapy PhI/II by one year, blames manufacturing". FierceBiotech. 14 October 2016. Retrieved 2021-04-23.
  3. "Adverum Biotechnologies, Inc (AAVL)". NASDAQ.com. Retrieved 4 January 2016.
  4. "Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA". finance.yahoo.com. Retrieved 2020-02-25.
  5. "ADVM-022 Intravitreal Gene Therapy for Wet AMD - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-02-25.
  6. Garde, Damian (2014-07-31). "Gene therapy biotech Avalanche banks $102M in an up-sized IPO". FierceBiotech. Archived from the original on 2021-04-13. Retrieved 2021-04-26.
  7. Leuty, Ron (2015-07-27). "As CEO exits, gene therapy company continues tumble". San Francisco Business Times. Retrieved 2021-04-23.
  8. "Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies". GlobeNewswire News Room. 2016-05-12. Retrieved 2020-02-25.
  9. "Post-merger, gene therapy player Adverum makes Amber Salzman CEO, delays a clinical trial start". Endpoints News. Retrieved 2021-04-23.
  10. Taylor, Nick Paul (2018-05-04). "Adverum loses CEO, CMO in quick-fire departures". FierceBiotech. Archived from the original on 2018-05-04. Retrieved 2021-04-23.
  11. "Adverum CEO Leone Patterson leaves her post | exechange". exechange.com. Retrieved 2021-04-23.
  12. "Adverum cannot hide under an avalanche of concerns". Evaluate.com. 2019-09-12. Retrieved 2021-04-24.
  13. "Adverum Biotechnologies Announces Leadership Transition". GlobeNewswire News Room. 2020-06-15. Retrieved 2021-04-23.
  14. David Hutton (January 6, 2022). "Adverum Biotechnologies gets Orphan Drug Designation from FDA for gene therapy candidate". Ophthalmology Times.
  15. David Hutton (September 16, 2022). "Adverum Biotechnologies announces first subject dosed with Ixo-vec in the Phase 2 LUNA trial for treatment of wet AMD". Ophthalmology Times.
  16. Noah Stansfield (September 16, 2022). "First Patient Dosed in Wet AMD Gene Therapy LUNA Trial". CGTlive.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.